Medical Influenza Vaccine(Split Virion)

 influenza Vaccine (Split Virion), Inactivated [Eligibles] Susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area. [Function and use] The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses. [Description] The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus. It is a slightly milky-white liquid, containing thimerosal as a preservative. Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. ) Subsidiary materials: All the components of subsidiary materials approved shall be listed. [Specifications] 0. 25 ml or 0.5 ml per container.  0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall co